Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure to Participate in 2026 Leerink Global Healthcare Conference
04:30pm, Friday, 27'th Feb 2026
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2026 Leerink Global Healthcare Conference.
NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates
01:21pm, Thursday, 26'th Feb 2026
NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago.
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
11:17am, Thursday, 26'th Feb 2026
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
07:00am, Thursday, 26'th Feb 2026
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of
Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know
11:00am, Thursday, 19'th Feb 2026
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
11:17am, Tuesday, 17'th Feb 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer
11:05am, Tuesday, 17'th Feb 2026
NVCR wins early FDA nod for Optune Pax in pancreatic cancer, boosting survival in phase III and opening TTFields-driven market.
Weekend Morning Brew: AI Jitters, Novo--Hims Clash, McDonald's Beat
07:37am, Saturday, 14'th Feb 2026
Weekly Market HighlightsWeekly breadth was slightly negative with 4,703 advancers versus 4,832 decliners, even as 963 stocks gained more than 10% and 1,151 fel
NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
05:38pm, Thursday, 12'th Feb 2026
NovoCure secures FDA approval for Optune Pax in first-line locally advanced pancreatic cancer, the first such approval in three decades. The company is positioned for further expansion with the phase
Market Today: Tech Sells Off on AI Jitters; M&A, FDA Moves and Policy Shifts
05:35pm, Thursday, 12'th Feb 2026
Guru Stock PicksAl Gore has made the following transactions:Reduce in NTNX by 46.77%Sold out in MCHPAdd in MELI by 2.52%New position in CSLKen Fisher has made t
Stock Market Today: Futures Rise After Dow Snaps 3-Session Winning Streak; Cisco Systems Shares Sink After Earnings
09:30am, Thursday, 12'th Feb 2026
Stocks were poised for a higher open Thursday, a day after major equities indexes ticked lower, with the Dow Jones Industrial Average snapping a three-session winning streak during which it set intrad
This Biotech Stock Is Jumping 25% After Getting an FDA Boost
06:53am, Thursday, 12'th Feb 2026
Novocure stock surged after the Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain pancreatic cancers.
Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report—Micron, Novocure, Fastly In Focus
06:19am, Thursday, 12'th Feb 2026
U.S. stock futures rose on Thursday following Wednesday's decline. Futures of major benchmark indices were higher after the strong January jobs report.
What's Happening With NovoCure Stock?
06:15am, Thursday, 12'th Feb 2026
NovoCure stock (NVCR) is up over 30% following the FDA's approval of its Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment in almost 30 years.
